We observed 1-year mortality in patients with type 2 diabetes who were prescribed GLP1-RAs to be substantially lower than patients not prescribed GLP1-RAs with a disproportionate benefit observed in those also diagnosed with OSA, says Cosmo Fowler, MD, lead researcher and CHEST 2025 presenter, in a release
The choice depends on medical advice, personal preference and how well the medication works for the individual
During your peptide therapy consultation in Florida, your provider may review different peptide options based on your goals, medical history, symptoms, medications, lab needs, and clinical appropriateness
243 , F271F275 (1982)
She said it was good to see the findings replicated in a separate database, from the National Institutes of Healths All of Us database, but would like to see more followup, because some other studies have not found a similar effect.